Taysha gene therapies to release full-year 2024 financial results and host conference call and webcast on february 26

Dallas, feb. 19, 2025 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a clinical-stage biotechnology company focused on advancing adeno-associated virus (aav)-based gene therapies for severe monogenic diseases of the central nervous system (cns), today announced that it will report its financial results for the full-year ended december 31, 2024, and host a corporate update conference call and webcast on wednesday, february 26, 2025, at 8:30 am eastern time. conference call details wednesday, february 26, at 8:30 am eastern time / 7:30 am central time toll free: 877-407-0792international: 201-689-8263conference id: 13751800webcast: https://ir.tayshagtx.com/news-events/events-presentations about taysha gene therapies taysha gene therapies (nasdaq: tsha) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (aav)-based gene therapies for severe monogenic diseases of the central nervous system.
TSHA Ratings Summary
TSHA Quant Ranking